key: cord-0904960-33xpcwzk
authors: Gargouri, Saba; Souissi, Amal; Abid, Nabil; Chtourou, Amel; Feki-Berrajah, Lamia; Karray, Rim; Kossentini, Hana; Ayed, Ikhlass Ben; Abdelmoula, Fatma; Chakroun, Olfa; Nasri, Abdennour; Hammami, Adnène; Rekik, Noureddine; Masmoudi, Saber; Karray-Hakim, Hela; Rebai, Ahmed
title: Evidence of SARS-CoV-2 Symptomatic Reinfection in Four Health Care Professionals from the Same Hospital Despite the Presence of Antibodies
date: 2022-01-10
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.01.006
sha: 204342daa634689c37aafadfd321cf8fdfa12afe
doc_id: 904960
cord_uid: 33xpcwzk

Objectives Since the onset of the COVID-19 pandemic, cases of reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported, raising additional public health concerns. SARS-CoV-2 reinfection was assessed in healthcare workers in Tunisia, as they are at the greatest exposure to infection by different variants. Methods We conducted whole-genome sequencing of the viral RNA from clinical specimens at the initial infection and suspected second infection from four healthcare workers, working at the Habib Bourguiba University Hospital (Sfax, Tunisia), who were retested positive for SARS-CoV-2 by RT-PCR after recovery from a first infection. A total of 8 viral RNAs from the patients’ respiratory specimens were obtained, which allowed us to characterize the differences between viral genomes from initial infection and positive retest. The serology status for total Ig, IgG, and IgM against SARS-CoV-2 was also determined and followed after the first infection. Results We confirmed by whole-genome sequencing of the viral samples that all four cases experienced a reinfection event. The interval between the two infection events ranged from 45 to 141 days and symptoms were milder in the second infection for two patients and more severe for the two remaining cases. Reinfection occurred for all four cases, despite the presence of antibodies for three of them. Conclusion This study adds to the rapidly growing evidence of COVID-19 reinfection, where viral sequences were used to confirm infection by distinct isolates of SARS-CoV-2 in healthcare workers. These findings suggest that individuals, who are exposed to different SARS-CoV-2 variants, might not acquire sufficiently protective immunity through natural infection and emphasis the necessity of their vaccination and the regular follow-up of their immune status both in quantitative and qualitative terms.

Since the onset of the COVID-19 pandemic, cases of reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported, raising additional public health concerns. SARS-CoV-2 reinfection was assessed in healthcare workers in Tunisia, as they are at the greatest exposure to infection by different variants.

We conducted whole-genome sequencing of the viral RNA from clinical specimens at the initial infection and suspected second infection from four healthcare workers, working at the Habib Bourguiba University Hospital (Sfax, Tunisia), who were retested positive for SARS-CoV-2 by RT-PCR after recovery from a first infection. A total of 8 viral RNAs from the patients" respiratory specimens were obtained, which allowed us to characterize the differences between viral genomes from initial infection and positive retest.

The serology status for total Ig, IgG, and IgM against SARS-CoV-2 was also determined and followed after the first infection.

We confirmed by whole-genome sequencing of the viral samples that all four cases experienced a reinfection event. The interval between the two infection events ranged from 45 to 141 days and symptoms were milder in the second infection for two patients and more severe for the two remaining cases. Reinfection occurred for all four cases, despite the presence of antibodies for three of them.

This study adds to the rapidly growing evidence of COVID-19 reinfection, where viral sequences were used to confirm infection by distinct isolates of SARS-CoV-2 in healthcare workers. These findings suggest that individuals, who are exposed to different SARS-CoV-2 variants, might not acquire sufficiently protective immunity through natural infection and emphasis the necessity of their vaccination and the regular follow-up of their immune status both in quantitative and qualitative terms.

Coronavirus disease 2019; SARS-CoV-2; Reinfection; Healthcare professional

Since the outbreak of the COVID-19 pandemic, the duration of immunity against infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been the subject of hot debate (Rhee et al. 2021) . Although, being infected by SARS-CoV-2 several times is a rare event, recent studies have reported confirmed reinfection cases (Dhillon et al. 2021) . A previous history of SARS-CoV2 infection was associated with an 84% lower risk of infection with median protective effect observed 7 months following primary infection (Hall et al. 2021 ).

Additionally, a large cohort study of antibody-positive individuals in Qatar showed that patients developed robust immunity following primary infection, lasting for at least seven months and protects against reinfection with an efficacy of ~95% (Abu-Raddad et al. 2021 ).

However, it has been reported that immunity from a mild infection does not last as long as a severe infection; a six-month follow-up of Chinese patients showed that neutralizing antibody titers decrease few weeks to few months after the infection and that this decrease is significantly faster in patients with milder symptoms (Huang et al. 2021) , suggesting that those who experience the mildest symptoms in their initial infection might have a higher likelihood of reinfection. Another study including 12,541 healthcare workers (HCWs) showed that the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months (Lumley et al. 2021 ).

Tomassini and collaborators defined reinfection as RT-PCR positivity at least 28 days after a previous RT-PCR-positive COVID-19 episode (Tomassini et al. 2021) , followed by clinical recovery and at least one negative RT-PCR. However, the confirmation of reinfection is only possible through whole genome sequencing of viral variants of samples from the first and second infection, yielding two different mutation settings or lineages. Although reinfection remains a rare event, several reports of confirmed reinfection, with variable symptom severity, have been reported. As of November 26 2021, the reinfection tracker website (https://bnonews.com/index.php/2020/08/covid-19-reinfection-tracker/) reported 544 confirmed cases of reinfection and over 190 thousand suspected cases.

For confirmed cases, the average interval between the two infection events is 115 day and 88% of the cases have shown mild to severe symptoms in the two infections.

As of June 5, 2021, more than two million people were registered in the national platform for vaccination in Tunisia, more than 1.6 million persons have been vaccinated since March 13, 2021 (as of June 23, 2021) and the campaign has given priority to HWC, after elderly people. This article represents our ongoing effort to follow the evolution of SARS-CoV-2 in clinical setting (Wilkinson et al. 2021 ).

The PubMed database was searched with different combinations of keywords including "COVID-19" "healthcare workers", "reinfection" and "secondary infection". We restricted our search to publications in English. As of June 5, 2021 only six publications confirmed the hypothesis of reinfection (Adrielle Dos Santos et al. 2021; Gupta et al. 2020; Selhorst et al. 2020; Loconsole et al. 2021; Brehm et al. 2021 ) through whole-genome sequencing, however not all have shown distinct variants for both infection episodes (Table S1 ).

We report here four cases of reinfection, all females and healthcare professionals (a medical doctor, a registrar agent working in emergency department and two health technicians), aged between 32 and 46 years ( She recovered without treatment and continued to feel well until December 17, 2020, when she experienced more severe symptoms (fatigue, headache, nasal congestion, chills, dyspnea, dizziness, and chest pain). The reinfection was confirmed on December 21, 2020 by RT-PCR (Ct=34.4). The symptoms were managed at home and she recovered one month later. The patient has been tested for total Ig, IgG, and IgM against SARS-CoV-2 since December 7, 2020 ( Figure 1C ).

Patient #4, a 46-year-old registrar agent with a history of Behçet disease, was first tested positive on September 21, 2020 after showing symptoms one week earlier (September 14, 2020). She recovered 10 days later (confirmed by negative RT-PCR on October 6, 2020) and

continued to feel well for three weeks. On October 29, 2020, she showed very severe symptoms requiring hospitalization and oxygen therapy combined with other treatments. The reinfection was confirmed by Real Time RT-PCR on November 6, 2020 (Ct=30.9). The recovery occurred after 6 days of treatments and was confirmed by a negative RT-PCR on

November 27, 2020. The patient was tested for total Ig, IgG, and IgM against SARS-CoV-2 on November 13, 2020 ( Figure 1D ).

Viral RNA was extracted from nasopharyngeal swab samples, collected between 0 and 8 days after the onset of symptoms ( 

Serological testing was performed for all patients using both an Enzyme Linked Fluorescent Assay (ELFA) for the detection of anti-Spike (S1) (specifically, anti-receptor binding domain (anti-RBD)) IgM and IgG (VIDAS® SARS-CoV-2 IgG and IgM, Biomérieux SA, France) and, a Chemiluminescent Immunoassay (CLIA), for the detection of anti-nucleocapsid (NP) total antibodies (Ab) (Elecsys Anti-SARS-CoV-2, on the Cobas e411, Roche Diagnostics, Germany).

cDNA synthesis was performed, using nasopharyngeal swab sample, by a high-fidelity multiplex PCR reaction for target enrichment using two pools of 400 bp QIAseq SARS-CoV- In order to make the fragments ready for the adapter ligation, the fragmented DNA was directly end-repaired through adding an "Adenine" to the 3" ends. Illumina specific adapters were then ligated to the DNA fragments in both ends. The reaction was cleaned-up to remove the adapter-dimers using 0.8X AMPure XP beads. Finally, we performed a high-fidelity amplification of sequencing libraries using the HiFi PCR Master Mix. The six amplification cycles were followed by a purification using 1X AMPure XP beads and finally a step of quality and quantity assessment was performed. All QIAseq FX DNA libraries were separately diluted to a concentration of 4 nM, then pooled together in equimolar amounts, denatured with 0.2 N NaOH and finally loaded at the recommended concentration (10 pM) onto a MiSeq sequencing System (Illumina, USA).

The raw data quality was checked using MiSeq Sequencing Analysis Viewer software. We obtained cluster densities ranging from 900,000 to 1 million clusters/mm 2 , and over 89% of generated bases were of Q30 value (with 85 % of clusters passing filter). Following the quality check, The FASTQ files were imported and analyzed using CLC Genomics

Workbench 20.0.3 (QIAGEN, Aarhus, Denmark). Briefly, the workflow performed on CLC genomics workbench included raw reads firstly trimmed based on read quality and to remove adapters.

A reference-based mapping was performed to each trimmed read that were mapped to the Wuhan SARS-CoV-2 reference genome SARS-CoV-2/human/CHN/Wuhan-01/2019 (NCBI Accession: NC_045512). From each mapping, we collected a consensus sequence, sequence variants and mapping coverage. Variant calling was performed and based on variant/amino acid change resulted tables we filtered the variants that met a minimum coverage of >30x, minimum coverage of five reads, minimum count of five, and greater than 70% of total reads carrying the variation.

To ascertain the repeatability of results, a second bioinformatics analysis was performed using an independent process and open-source tools. We assessed the quality of the Illumina pairedend reads using FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). We aligned the reads to the reference genome using the standalone Burrows-Wheeler Alignment tool (BWA) ver. 0.7.17-r1188 (Li 2013) . We have used paired-end mode for mapping reads to the SARS-CoV-2 reference genome (NC_045512, version NC_045512.2). We used SAMtools ver. 1.7 (using htslib 1.7-2) to convert the output of BWA from SAM to BAM format, and to sort and generate indices for the BAM files (Li et al. 2009 ). We carry out two rounds of filtration (by length cutoff 100 and quality cutoff 60) and the results were analyzed using Integrative Genomics Viewer (IGV) ver. 2.8.9 (Robinson et al. 2017 7.310 (Katoh et al. 2002) . Gaps, incomplete sequences, and sequences showing low coverage were trimmed from the MSA. The duplicate sequences were removed using sRNAtoolbox (Rueda et al. 2015) . We carried out phylogenetic analysis using maximum likelihood (ML) method and the best tree was picked up according to their ML score using IQ-TREE multicore version 1.6.12 (Nguyen et al. 2015) using evolutionary model GTR+F+I+G4 Major SARS-CoV-2 clade memberships and the worldwide distribution of S477 mutation were predicted using Nextclade (Hadfield et al. 2018 ).

The time course between the two episodes of COVID and 20A (one case; lineage B.1) (Figure 2 , Table S2 ).

The clade 20A.EU2 emerged in the beginning of the pandemic, but by July 2020 it became the dominant form of clades, circulating globally and mainly in Europe ( Figure 3A and 3B (Figure 4) .

Additionally, if we examine the frequency trend of the S477N mutation based on data in GISAID, we see a clear increasing corresponding to the second wave of COVID-19 in Europe during the summer period of 2020 ( Figure 3C ) (Hodcroft et al. 2020 ).

All patients tested prior to the second infection (patients 1, 2 and 3) ( Table 2) were positive for anti-S1 IgG and negative for anti-S1 IgM, suggesting the presence of residual immunity at the time of reinfection. Anti-NP total Ab were detected only in two cases (patients 1 and 2).

For patient #1, further serological testing after 12 days showed a significant increase in IgG concentration, which were maintained for up to one month later. Similarly, a sustainable response for anti-S1 IgG was observed for patient #2, approximately 3 months after the first testing. Surprisingly, for patient #3, a progressive decline in IgG response seemed to occur despite the second episode of infection.

Unfortunately, no serum was available prior to reinfection for patient #4, who was first tested 15 days after symptoms onset during the second episode. At this time, both anti-S1 IgM and IgG were positive along with a weakly positive anti-NP total Ab. Further testing performed 5 months later showed the absence of IgM, with detectable IgG.

In summary our results show that the variants" features of first and second infections are different in all four cases, providing irrefutable evidence for reinfection, despite the presence of anti-S1 IgG.

The diagnosis of SARS-CoV-2 reinfection is currently based on the evidence of a new infection by a phylogenetically distinct form of the SARS-CoV-2 virus after the elimination of the previous one. In our case series of four HCW who have experienced two separate symptomatic episodes of COVID-19, distinct viral lineages were documented by comparative genome analysis. The presence of presumed residual immunity at the time of reinfection for three patients raises the concern about the protective role of immunity following COVID-19.

It has been reported in the literature that SARS-CoV-2 infection results in protection against symptomatic illness in HCWs at least in the short term (Lumley et al. 2021) . Furthermore, in the same study by Lumley et al. no symptomatic reinfections in HCWs with anti-spike antibodies were observed suggesting that previous infection resulting in antibodies to SARS-CoV-2 is associated with protection from reinfection for most people for at least 6 months (Lumley et al. 2021 (Annavajhala et al. 2021) . The S477N/D614G double mutation appeared in Australia during July and August 2020 and was traced to a single event from Australian hotel quarantine (Chen et al. 2020 ) and it currently represents 3 % of the submitted sequences in GISAID (at the date of June 5, 2021).

According to recent studies, variants with the S477N mutation have stronger binding of the spike protein to the human receptor ACE2 (Singh et al. 2021) and were resistant to neutralization by multiples mAbs (Z. Liu et al. 2021) . Therefore, the emergence of S477N/D614G could result in an immune evasive variant leading to less antibody binding and a resistance to virus neutralization. Additionally, it was shown that S477N/D614G is broadly resistant to many neutralizing antibody (Tea et al. 2021 ). Liu and collaborators also reported that some variants, including those with S477N and E484K mutations are resistant to, or escape neutralization by multiple monoclonal antibodies, suggesting a possible reinfection by these viral variants, of previously infected patients (L. Liu et al. 2020) .

The presence of S477N mutation in the spike protein may explain the occurrence of symptomatic reinfection in our four cases. Indeed, this mutation causes a higher affinity of S1 towards the cellular receptor ACE2 than the wildtype virus, hence, suggesting that interference with such binding between S1 and ACE2 through neutralizing antibodies will require higher affinity of these antibodies. Nevertheless, the factors that determine the outcome of reinfection remain unclear. Although the S477N mutation was uniformly carried in all subvariants isolated after secondary infection, the clinical presentation in our cases was heterogeneous, ranging from mild to severe forms. The quality of humoral and cell-mediated immunity responses against the virus might play a major role in determining the clinical outcome of COVID-19 reinfection.

Interestingly, in this report, while patients # 1 and 2 experienced a milder course of infection during the second episode with a faster recovery, patients # 3 and 4 showed a more severe secondary infection, requiring oxygen support with indication of hospitalization in one case (patient #4). The analysis of serum antibody profile of patient #1 clearly showed the decline in the anti-S1 IgG concentration between October 16 (10.04) and January 07 (3.46), which corresponds to the day of re-positive RT-PCR. This finding is in line that a decline in anti-S1

IgG precedes secondary infection (To et al. 2020, 1) . Furthermore, as a consequence of secondary infection, for patients #1 and 2, the IgG concentration is rising to substantially higher levels. This indicates that secondary infection enhances IgG production, and also might improve the quality of the response, specifically its affinity/avidity. This adequate and more robust antibody response may be the cause of the less intense and rapidly resolved reinfection (To et al. 2020, 1) .

Recently, it has been demonstrated that in SARS-CoV-2 infected individuals, the IgG response is characterized by incomplete avidity maturation, in contrast to two rounds of vaccination (Struck et al. 2021) . Incomplete avidity maturation might facilitate secondary SARS-CoV-2 infections and thus prevent the establishment of herd immunity (Bauer 2021; Struck et al. 2021) . Interestingly, Struck et al. also show that the combination of natural infection with one step of vaccination leads to the same degree of high avidity of IgG as two rounds of vaccination, hence improving the protective immunity status.

In contrast to patients #1 and 2, patient # 3 who has much more severe symptoms, does not

show an increase in anti-S1 IgG responses after secondary infection. This finding suggests that the more severe clinical outcome observed in this patient may be in relation, at least in part, with inadequate antibodies response during reinfection. For patient #4, the lack of a serological test prior to the second episode do not allow us to conclude to the presence or absence of a residual immunity. However, the presence of both anti-S1 IgG and IgM, 15 days after symptoms onset during reinfection suggests the absence of antibodies prior to reinfection, especially in this patient"s context. Indeed, the underlying condition along with immunosuppressive drugs might have compromised the antibodies response, leading to a more severe clinical presentation during the second infection. Of note, for patients #3 and 4, the interval between the two episodes of SARS-CoV-2 infection was 64 and 45 days, respectively. This is in line with a recent study, showing that the second episode of SARS-CoV-2 positivity is more severe if it happens within 60 days after the first positive PCR (Váncsa et al. 2021, 2) . Altogether, our results support the close association between the outcome of reinfection and the immunity response of the host; an inadequate immunity developed after the first infection may predispose to an early reinfection with more severe clinical presentation, especially in case of HCW who are frequently exposed to SARS-CoV-2.

This case study brings new evidence for the possibility of reinfection with COVID-19 and highlights the different clinical pictures that may occur during this reinfection. Nevertheless, in our study, it was not possible to fully assess the effectiveness of the immune response during the two episodes of SARS-CoV-2 infection, since neutralizing antibody titer against viral strains was not measured.

In Summary, our findings highlight the importance of measures to protect HCW during the pandemic, such as providing suitable protection devices and giving them priority for vaccination, even for those who have recovered from COVID-19. Our analyses also suggest that HCW who have had the virus should still be vaccinated. Whether the risk of reinfection in HCW is higher than in the general population is still an open question; further investigations are still needed to address this issue, especially under the moving landscape of viral variants.

FASTA-format sequences of complete viral genomes and metadata are available online through GISAID (http://gisaid.org). The datasets generated and analyzed during the present study are also available from the corresponding author on request

All authors declare no competing interest.

The study protocol adhered to the declaration of Helsinki and was approved by the ethic Committee of protection of persons (Tunisian Ministry of Health) under the reference CPP SUD N°0265/2020.

The work was funded by grants from the Ministry of Higher Education and Scientific

Research Tunisia to the ADAGE consortium (reference: PRFCOVID19GP2) and from the Ministry of Health, Tunisia. The funders had no role in study design, data collection, data analysis, data interpretation or writing for the report. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.

SG contributed to the design of the study, sample processing, immunological data analyses, and writing of the paper. AS contributed to genome sequencing, sequence assembly and writing of the paper. NA contributed to sequence assembly, sequence analyses, phylogeny, figures and tables" production and writing and editing of the paper. AC contributed to samples processing and analyses. LFB contributed to samples processing and analyses and manuscript editing. RK, HK, OK and AN contributed to case identification, clinical care and collection of clinical data. AH, NR and HKH and SM supervised the work. AR contributed to the study design, data analyses, writing/editing of the paper and is coordinator of the ADAGE consortium. CT scan showed bilateral ground glass opacities, the pulmonary involvement was estimated to be around 25% Results are obtained for anti-S1 antibodies as an index value (i) = Sample/S1 standard; a sample is considered as negative if (i) < 1.00 and as positive if (i) ≥ 1.00. Results for anti-NP antibodies are obtained as a ratio = Sample/CO (cut-off); a sample is considered as negative if S/CO ratio < 1.00 and as positive if S/CO ratio ≥ 1.00. c Ct = Cycle threshold Table 3 . Variants of SARS-CoV-2 from reinfection cases" samples. 

« SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

« Recurrent COVID-19 Including Evidence of Reinfection and Enhanced Severity in Thirty Brazilian Healthcare Workers

et Anne-Catrin Uhlemann. 2021. « A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York ». MedRxiv, février

The Potential Significance of High Avidity Immunoglobulin G (IgG) for Protective Immunity towards SARS-CoV-2 ». International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases

« SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies

COVID-19 CG: Tracking SARS-CoV-2 Mutations by Locations and Dates of Interest

Mir Ibrahim Sajid, et Syed Faisal Mahmood. 2021. « The Mystery of COVID-19 Reinfections: A Global Systematic Review and Meta-Analysis

« Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2 ». Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, septembre, ciaa1451

« Nextstrain: Real-Time Tracking of Pathogen Evolution

« SARS-CoV-2 Infection Rates of Antibody-Positive Compared with Antibody-Negative Health-Care Workers in England: A Large, Multicentre, Prospective Cohort Study (SIREN)

« Emergence and Spread of a SARS-CoV-2 Variant through Europe in the Summer of

« 6-Month Consequences of COVID-19 in Patients Discharged from Hospital: A Cohort Study

« Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR »

« MAFFT: A Novel Method for Rapid Multiple Sequence Alignment Based on Fast Fourier Transform

« Interactive Tree Of Life (ITOL) v4: Recent Updates and New Developments »

« Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM

et 1000 Genome Project Data Processing Subgroup

« Landscape Analysis of Escape Variants Identifies SARS-CoV-2 Spike Mutations That Attenuate Monoclonal and Serum Antibody Neutralization

et Maria Chironna. 2021. « Symptomatic SARS-CoV-2 Reinfection in a Healthy Healthcare Worker in Italy Confirmed by Whole-Genome Sequencing

« Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies

« Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?

« Variant Review with the Integrative Genomics Viewer »

« SRNAtoolbox: An Integrated Collection of Small RNA Research Tools

Hilde Jansens, et Kevin K. Ariën. 2020. « Symptomatic SARS-CoV-2 Reinfection of a Health Care Worker in a Belgian Nosocomial Outbreak despite Primary Neutralizing Antibody Response ». Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, décembre, ciaa1850

« Serine 477 Plays a Crucial Role in the Interaction of the SARS-CoV-2 Spike Protein with the Human Receptor ACE2 »

Manfred Motz, et Georg Bauer. 2021. « Vaccination versus Infection with SARS-CoV-2: Establishment of a High Avidity IgG Response versus Incomplete Avidity Maturation »

Breadth, and Evasion by Emerging Viral Variants

« Serum antibody profile of a patient with COVID-19 reinfection ». Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, septembre, ciaa1368

2021. « Setting the Criteria for SARS-CoV-2 Reinfection -Six Possible Cases

Repeated SARS-CoV-2 Positivity: Analysis of

A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa

Tunisia for the ADAGE consortium (PRFCOVID19GP2) and from the Ministry of Health, Tunisia.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: